Alnylam Pharmaceuticals, Inc. (ALNY) stock
ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$149.40−7.10 (-4.54%)
Close on Nov 18, 2026Market cap $20.01BP/E 7.8Yield –
Alnylam Pharmaceuticals pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Alnylam Pharmaceuticals's pe ratio was 28.1× on Nov 11, 2026, against 564.0× a year earlier.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 28.1× | −468.9 |
| 2025 | Dec 31, 2025 | 497.1× | – |
See a number that looks wrong?